Progesterone
metaboliteProgesterone accumulation in CYP17A1 deficiency reflects dysregulated lipid and steroid metabolism implicated in atherosclerosis susceptibility.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleSteroid accumulation in CYP17A1 deficiency; systemic hormonal marker.
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- CYP17A1 deficient XY mice display susceptibility to atherosclerosis, altered lipidomic profile and atypical sex development.Scientific reports · 2020 · PMID 32472014 · doi